Fragment 176-191 vs AOD-9604

Derivation from Growth Hormone

Human growth hormone (hGH) is a 191-amino acid pituitary protein with multiple biological domains. Early research by researchers at Monash University (Australia) identified that the C-terminal region of hGH — roughly amino acids 177–191 — contains the domain responsible for GH's lipolytic (fat-mobilizing) activity, independent of the N-terminal domain responsible for IGF-1 stimulation and growth promotion.

This discovery led to the hypothesis that isolated C-terminal GH fragments could replicate GH's fat-reduction effects without GH's diabetogenic and growth-stimulating side effects — making them potential research tools for obesity biology.

Structural Difference

The key structural distinction between the two compounds:

• Fragment 176-191: Corresponds directly to amino acids 176–191 of hGH: Leu-Arg-Ile-Val-Gln-Cys-Arg-Ser-Val-Glu-Gly-Ser-Cys-Gly-Phe. The two cysteine residues (positions 182 and 189 in native GH, or Cys-6 and Cys-13 in the fragment) form a disulfide bridge creating a cyclic structure considered important for activity.
• AOD-9604 (Anti-Obesity Drug 9604): The same fragment with a tyrosine (Tyr) residue added to the N-terminus: Tyr-Leu-Arg-Ile-Val-Gln-Cys-Arg-Ser-Val-Glu-Gly-Ser-Cys-Gly-Phe. The tyrosine was added to improve stability and enable radiolabeling for pharmacokinetic studies. Developed under the pharmaceutical development program at Metabolic Pharmaceuticals (now Calzada).

In practice, most published cell culture and animal studies showing lipolytic effects were performed with AOD-9604 (the Tyr-containing form). Some literature conflates the two — researchers should note which exact form was used.

Lipolytic Mechanism

Both fragments are proposed to act through a receptor distinct from the full-length GH receptor (GHR), though the specific receptor has not been identified and characterized. Proposed mechanisms from published research:

• β3-adrenergic receptor (β3-AR) stimulation: Some in vitro data suggests Fragment 176-191 activates β3-AR on adipocytes, the primary receptor mediating catecholamine-induced lipolysis in brown and white adipose tissue
• Hormone-sensitive lipase (HSL) activation: Increased HSL phosphorylation and activity observed in adipocyte cell cultures treated with AOD-9604
• No GHR binding: Multiple binding studies confirm that Fragment 176-191 and AOD-9604 do not bind the full-length GH receptor — explaining the absence of GH's typical effects (IGF-1 stimulation, hyperglycemia, growth promotion)

Glycemic Neutrality

One of the most important research findings for both compounds:

Full-length GH at pharmacological doses causes insulin resistance and elevated blood glucose — a major safety concern for GH-based obesity treatments. Fragment 176-191 and AOD-9604 do not activate the GH receptor and therefore do not produce this effect.

In both the preclinical rodent studies and the AOD-9604 Phase II clinical trials, no significant effects on fasting blood glucose, insulin levels, or HOMA-IR were observed. This glycemic neutrality — combined with lipolytic activity — was the primary pharmacological rationale for clinical development.

AOD-9604 Clinical Trial History

AOD-9604 has the most extensive clinical trial history of any research peptide in the lipolytic/obesity category:

• Phase II obesity trial (2001–2004): Placebo-controlled 12-week study in overweight/obese adults. Results: modest fat loss (~1 kg mean at highest dose vs. placebo) — statistically significant in some subgroups but insufficient for Phase III advancement as a first-line obesity drug.
• Safety profile: No serious adverse events attributable to treatment in Phase II. No antibody formation against the fragment (important as it's a GH domain — immune tolerance was a concern).
• Osteoarthritis (Phase II, 2012–2016): AOD-9604 was investigated for cartilage repair by intra-articular injection under the program name "Tyr-hGH176-191." Published Phase II data showed no significant benefit vs. placebo on the primary endpoint (WOMAC score).
• Current status: No approved indication. Development rights held by Calzada (formerly Metabolic Pharmaceuticals). Research interest continues in preclinical adipose tissue biology models.

Comparison Table